On May 3, 2022 PharmaMar (MSE:PHM) reported that Clinical Cancer Research, the journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), has published the manuscript titled "Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study", led by Vivek Subbiah M.D. (MD at the Anderson Cancer Center, Houston, USA) (Press release, PharmaMar, MAY 3, 2022, View Source [SID1234613403]). The manuscript is available at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This abstract shows the results of the 28-patient cohort of adult patients with relapsed Ewing Sarcoma from the single-arm, open-label, basket phase II clinical trial with single-agent lurbinectedin.
The trial achieved its primary endpoint of Overall Response Rate (ORR) of 14.3%, with a median Duration of Response (DoR) of 4.2 months. In addition, other secondary endpoints such as a median Progression-Free Survival (PFS) of 2.7 months, a clinical benefit ratio of 39.3% and a disease control ratio of 57.1% were achieved.
The abstract concludes "lurbinectedin was active in the treatment of relapsed Ewing Sarcoma and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for Ewing Sarcoma, and is currently being evaluated in combination with irinotecan in advanced Ewing Sarcoma in a phase Ib/II trial."
According to Ali Zeaiter M.D., Director of Clinical Development at PharmaMar,
"Ewing sarcoma is an aggressive disease afflicting primarily children through to young adults under 20 years of age, so it is a particular unmet medical need in this regard with no established treatment for relapsed disease. This study has shown encouraging activity in this setting with a manageable safety profile and we are continuing to explore the potential of lurbinectedin in this setting."